GlassScriptPhysician profile
Dixie L Knoll
NPI 1235330390
$1,510.15
in general payments reported to CMS, 2019-2025
26 companies · $858 in 2025
The $858 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.33 · 2022: $81.23 · 2023: $251 · 2024: $264 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $329.03 | 2024-2025 | Enhertu |
| Daiichi Sankyo INC. | $208.06 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Gilead Sciences, INC. | $127.59 | 2023-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $105.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.06 | 2024 | Ninlaro |
| Janssen Biotech, INC. | $78.05 | 2025 | Erleada, Rybrevant |
| Incyte Corporation | $54.22 | 2025 | Jakafi, Niktimvo, Zynyz |
| Astellas Pharma US INC | $52.32 | 2025 | Xtandi, Vyloy |
| Adc Therapeutics America, INC. | $51.39 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.69 | 2025 | Opdivo |
| Genzyme Corporation | $43.70 | 2023-2025 | |
| Novocure INC. | $40.55 | 2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $35.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $32.74 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $28.88 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $23.48 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $22.19 | 2025 | |
| Sobi, INC | $20.85 | 2025 | |
| Eisai INC. | $19.49 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.38 | 2024 | Tavalisse, Rezlidhia |
| Tolmar, INC. | $18.18 | 2025 | |
| Stemline Therapeutics INC. | $16.73 | 2025 | Orserdu |
| Coherus Oncology, INC. | $16.32 | 2024 | |
| Pfizer INC. | $15.70 | 2025 | |
| Caris Mpi, INC. | $13.67 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixie Knoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.